Servier agreed to acquire Day One Biopharmaceuticals for about $2.5 billion in cash, securing Ojemda (tovorafenib), an FDA‑approved therapy for pediatric low‑grade glioma, and Day One’s early‑ to late‑stage oncology pipeline. The companies expect the transaction to close in the second quarter. Servier said the acquisition complements its existing rare‑cancer strategy and bolsters its U.S. oncology presence. Day One’s Ojemda posted roughly $155 million in 2025 sales; Servier will add the drug to its portfolio alongside Voranigo, another brain‑tumor therapy acquired earlier. Day One’s shares jumped by roughly 65% on the takeover news, reflecting investor approval of the premium deal structure. Servier plans to fund the purchase with cash and investments and cited a strategic commitment to rare cancer R&D and commercialization. The acquisition gives Servier immediate commercial scale in pediatric neuro‑oncology while adding experimental programs across adult and pediatric solid tumors. Analysts say the move accelerates consolidation in niche oncology where approved assets and targeted pipelines command premiums.